We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




X-ray Crystallography Study May Lead to New Drugs to Block Cancer Metastasis

By LabMedica International staff writers
Posted on 28 Apr 2016
Cancer researchers expect that the structure of the enzyme P-Rex1 (PIP3-dependent Rac exchanger 1), which was recently established by X-ray crystallography, will lead to development of a new generation of cancer chemotherapeutic agents to block the processes leading to metastasis.

P-Rex1 is a Rho guanine nucleotide exchange factor synergistically activated by the lipid PIP3 (phosphatidylinositol 3,4,5-trisphosphate) that plays an important role in the metastasis of breast, prostate, and skin cancer, which makes it an attractive therapeutic target. More...
However, the molecular mechanisms behind P-Rex1 regulation have been poorly understood.

Investigators at the University of Michigan (Ann Arbor, USA) used X-ray crystallography to determine structures of the P-Rex1 pleckstrin homology domain (a protein domain of approximately 120 amino acids that occurs in a wide range of proteins involved in intracellular signaling) bound to the headgroup of PIP3.

They reported in the April 14, 2016, online edition of the journal Structure that PIP3 binding to the pleckstrin homology domain was required for P-Rex1 activity in cells but not for membrane localization, which pointed to an allosteric activation mechanism by PIP3.

"P-Rex1 has been an attractive drug target for some time," said senior author Dr. John J.G. Tesmer, professor of pharmacology and biological chemistry at the University of Michigan. "But development of these drugs has been hindered by a lack of understanding of its structure and regulatory mechanisms. Our data have confirmed the location of the binding site, which will greatly assist with the identification or design of small molecules that target this mechanism of activation."

Related Links:
University of Michigan


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.